Eikon Therapeutics, Inc.’s (NASDAQ:EIKN) Lock-Up Period Set To End Tomorrow

Eikon Therapeutics’ (NASDAQ:EIKN) lock-up period is set to expire on Tuesday, August 4th. Eikon Therapeutics had issued 21,177,600 shares in its IPO on February 5th. The total size of the offering was $381,196,800 based on an initial share price of $18.00. After the end of Eikon Therapeutics’ lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on EIKN. Weiss Ratings started coverage on Eikon Therapeutics in a report on Monday, June 1st. They issued a “sell (e-)” rating for the company. Wall Street Zen downgraded Eikon Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, April 5th. Wedbush cut their price target on shares of Eikon Therapeutics from $7.00 to $5.00 and set an “underperform” rating on the stock in a report on Tuesday, May 12th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Eikon Therapeutics in a research note on Tuesday, June 2nd. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $25.20.

Eikon Therapeutics Price Performance

Shares of NASDAQ EIKN opened at $9.21 on Monday. Eikon Therapeutics has a twelve month low of $7.90 and a twelve month high of $17.40. The company has a market cap of $498.62 million and a P/E ratio of -3.74. The firm has a 50 day moving average price of $10.12.

Eikon Therapeutics (NASDAQ:EIKN) last issued its earnings results on Monday, March 30th. The company reported ($26.23) earnings per share for the quarter.

About Eikon Therapeutics

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.